- Home
- IOR vs GALT Comparison
IOR vs GALT Comparison
Compare IOR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- GALT
- Stock Information
- Founded
- IOR 1984
- GALT 2000
- Country
- IOR United States
- GALT United States
- Employees
- IOR N/A
- GALT N/A
- Industry
- IOR Real Estate Investment Trusts
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- IOR Real Estate
- GALT Health Care
- Exchange
- IOR Nasdaq
- GALT Nasdaq
- Market Cap
- IOR 75.2M
- GALT 83.5M
- IPO Year
- IOR N/A
- GALT N/A
- Fundamental
- Price
- IOR $18.90
- GALT $2.45
- Analyst Decision
- IOR
- GALT Buy
- Analyst Count
- IOR 0
- GALT 2
- Target Price
- IOR N/A
- GALT $6.00
- AVG Volume (30 Days)
- IOR 406.0
- GALT 1.4M
- Earning Date
- IOR 08-07-2025
- GALT 08-12-2025
- Dividend Yield
- IOR N/A
- GALT N/A
- EPS Growth
- IOR N/A
- GALT N/A
- EPS
- IOR 1.10
- GALT N/A
- Revenue
- IOR N/A
- GALT N/A
- Revenue This Year
- IOR N/A
- GALT N/A
- Revenue Next Year
- IOR N/A
- GALT N/A
- P/E Ratio
- IOR $17.24
- GALT N/A
- Revenue Growth
- IOR N/A
- GALT N/A
- 52 Week Low
- IOR $15.69
- GALT $0.73
- 52 Week High
- IOR $19.30
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- IOR 68.66
- GALT 61.39
- Support Level
- IOR $17.95
- GALT $2.21
- Resistance Level
- IOR $19.30
- GALT $3.90
- Average True Range (ATR)
- IOR 0.08
- GALT 0.47
- MACD
- IOR 0.06
- GALT 0.09
- Stochastic Oscillator
- IOR 70.37
- GALT 40.84
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.